Kitea Health

What Kitea Health does

Kitea Health is an Auckland, New Zealand-based medical device company developing the Kitea System, a micro-implantable intracranial pressure (ICP) sensor paired with an external wand reader that enables remote, real-time pressure measurement for patients with hydrocephalus. Founded in 2022 and spun out of research from the University of Auckland's Auckland Bioengineering Institute, the company is led by CEO and co-founder Simon Malpas (Professor of Physiology and Bioengineering and Fellow of the Royal Society of New Zealand), with Bryon Wright as CTO and Natalia Lopez as COO. The Kitea System addresses a clear unmet need: pediatric hydrocephalus patients face a 50% shunt failure rate within two years, and approximately 70% of hydrocephalus-related hospital admissions are deemed unnecessary, with annual US healthcare costs estimated at $2 billion across roughly 1 million affected patients.

The core technology is a sub-cranial implantable pressure sensor that communicates with an external handheld reader, allowing pressure data to be captured at home and in clinical settings rather than only through hospital-based invasive monitoring. The device is investigational and not yet approved for clinical use. First-in-human trials were completed at Auckland Hospital in mid-2024 with results peer-reviewed and published in Nature Communications in April 2025, and clinical partners include Starship Children's Hospital (Auckland), Children's Hospital of Orange County (Dr. Michael Muhonen), and Texas Children's Hospital (Dr. David Bauer). The company is also exploring the same sensor platform for heart failure management.

Kitea Health is pre-commercial and pursues a B2B medtech go-to-market focused on neurosurgery departments, hospital systems, and healthcare payers in the United States, with commercialization contingent on FDA approval. Revenue is expected to be generated through sale of the implantable device (and external reader hardware) with potential recurring revenue from associated remote physiological monitoring services. The company has raised approximately NZ$6M (March 2023, led by Pacific Channel) and US$13M (December 2025, over-subscribed) from a syndicate of New Zealand and Australian investors including Icehouse Ventures, NZ Growth Capital Partners, Bioshore Ventures, Enterprise Angels, ArcAngels, Cure Kids Ventures, Flying Kiwi Angels, and KP Rx. A US office in Camden, Delaware supports regulatory affairs, and the board includes medtech operators Harry Rowland (former Endotronix CEO/Chair) and P. Laxminarain (former Worldwide President of J&J Codman).

Name

Kitea Health

Legal name

Kitea Health Ltd

Website

https://kiteahealth.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Kitea Health is an Auckland-based medical device company developing the Kitea System, a micro-implantable intracranial pressure sensor that enables remote monitoring for hydrocephalus patients, with commercialization pending FDA approval in the United States.

Ownership category

akta.pro rank

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Medical Device Sales: Kitea Health plans to generate revenue through the sale of the Kitea System (implantable medical devices) to hospitals and healthcare systems. The device is currently investigational and not commercially available. Revenue will be generated upon regulatory approval (FDA and other jurisdictions).
2. Remote Monitoring Services: The system enables remote physiological monitoring, suggesting a potential recurring revenue model through monitoring services, data access, or software components associated with the device ecosystem.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Kitea Health develops the Kitea System, a micro-implantable intracranial pressure (ICP) sensor platform intended for remote monitoring of patients with hydrocephalus (and potentially heart failure). The system combines an implantable sensor with an external reading wand, enabling pressure measurement at home and in hospital for the first time to support early detection of shunt failure and pressure-guided chronic disease management. The product is currently investigational and not yet commercially available, pending regulatory approval (including FDA) in target markets.

Product overview

Kitea Health is a medical technology company offering a single unified product platform called the Kitea System. The system consists of a micro-implantable intracranial pressure sensor and an external wand device that enables remote, real-time pressure monitoring for patients with hydrocephalus. The investigational device aims to transform reactive shunt failure management into proactive, pressure-guided care by enabling measurements outside clinical settings. The company is also developing the technology for heart failure applications based on research from the University of Auckland.

Differentiator

Problem solved

Functional benefit

Brands

• The Kitea System: Next generation micro-implantable device system for pressure-guided management of chronic disease, enabling remote intracranial pressure monitoring for hydrocephalus patients

Products and services

• Kitea System The Kitea System is an investigational micro-implantable intracranial pressure (ICP) sensor platform that pairs an implantable sensor with an external reading device (wand), enabling patients and clinicians to measure intracranial pressure at home and in hospital. It is designed to support pressure-guided management of hydrocephalus (and potentially heart failure), reduce unnecessary hospital admissions, and enable early detection of shunt failure. The product is intended for hospitals, neurosurgery departments, and healthcare payers, and is currently investigational, pending regulatory approval (including FDA) in target markets.

Quantifiable outcome

• Estimated 30% reduction in healthcare costs through application of Kitea device
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• University of Auckland - Auckland Bioengineering InstitutecoreStrategic or Co-development PartnerResearch partnership with the University of Auckland's Auckland Bioengineering Institute. The technology is based on research from this institution, and Professor Simon Malpas holds a position there. Collaboration on sensor technology development and clinical research.
• UniservicescoreStrategic or Co-development PartnerUniversity of Auckland's commercial arm that helps translate research into commercial outcomes. Partnered with Kitea Health for technology commercialization from academic research.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Endotronix (Edwards Lifesciences): Developed the Cordella implantable pulmonary artery pressure sensor for heart failure, achieving FDA PMA and being acquired by Edwards Lifesciences in 2024. The most direct comparable in business model and technology (chronic implantable pressure sensor with remote monitoring), and shares the same Chair (Harry Rowland) who led Endotronix.

Broad incumbents

• Medtronic: Global medtech incumbent with the dominant hydrocephalus shunt franchise (Strata, Hakim, etc.) and broad neurosurgery sales force. Represents both the primary competitive threat and a likely strategic acquirer of remote ICP monitoring technology.
• Integra LifeSciences: Major neurosurgery device company with established hydrocephalus product lines and ICP monitoring products. Overlaps directly with Kitea's target neurosurgery call point and patient population.
• Johnson & Johnson Medtech (Codman): Codman division is a long-standing leader in hydrocephalus shunts and neurosurgical products. Kitea board member P. Laxminarain was previously Worldwide President of Codman, making J&J Medtech both a key competitor and a natural strategic acquirer.
• Penumbra: Neurovascular device company expanding into neurosurgery and stroke care. Comparable in targeting the same neurosurgery call point and increasingly competing for hospital neurosurgery budgets.
• Stryker: Broad medtech incumbent with significant neurosurgery and neurotechnology franchises (acquisitions of Wright Medical, etc.). Competes for neurosurgery capital budgets and represents a likely strategic acquirer for differentiated neurotech assets.
• Brainlab: Digital surgery and radiotherapy company with a strong neurosurgery installed base and software platform. Potential integration partner for adding pressure data into the neurosurgical planning and OR workflow.

Emerging players

• Raumedic: Specializes in invasive and non-invasive ICP monitoring and external CSF drainage systems. Closest existing pure-play in ICP monitoring, though focused on acute/intra-hospital settings rather than chronic at-home implants.
• Senseonics: Developer of the Eversense implantable continuous glucose monitoring system, the longest-duration implantable sensor commercially available. Directly analogous in chronic disease implantable sensor business model and remote patient monitoring economics.
• CereVasc: Early-stage neurovascular company developing the eShunt system as an alternative to traditional shunts for hydrocephalus. Represents a competing technology approach to the same patient population, with overlapping clinical KOLs in neurointervention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kitea-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kitea Health